Comparing The Efficacy of Alternating Citrate and Heparin lock Vs. Heparin Alone in Chronic Hemodialysis : A Randomized Control Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251021002

Enrollment

Registered

2025-10-21

Start date

2024-10-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage kidney disease with chronic hemodialysis with tunnel cuff permanent catheter ESKD, Chronic hemodialysis, Catheter-Related Infection (CRI), Catheter-Related Thrombosis (CRT), Hemodialysis Catheter, Catheter Locking Solution, Heparin, Citrate

Interventions

A 30 percent sodium citrate solution (1.8 to 2.5 mL, depending on the catheter type) is instilled as a locking solution, alternating with 2,500 to 5,000 U/mL heparinLeo (1.8 to 2.5 mL, depending on th

s pre-study heparin prescription.Specifically, a 30 percent sodium citrate solution will be used for short interdialytic periods, while heparin solution will be used for longer interdialytic periods.

s pre study heparin prescription.

Active Comparator Drug,No Intervention Drug

alternating citrate and heparin catheter lock,Heparin lock (standard treatment)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients aged above or equal to 18 years. 2.Patients who have been using a tunneled cuff central venous catheter for chronic hemodialysis for at least 3 months. 3.Patients who are able to provide informed consent. 4.Patients with clinically stable condition for at least 1 month (defined as no history of catheter-related infection, no history of catheter dysfunction/occlusion, and no hospitalization within the past month).

Exclusion criteria

Exclusion criteria: 1.Patients with a bleeding tendency (e.g., liver cirrhosis Child-Pugh class B or C, history of heparin-induced thrombocytopenia, or platelet count under 100,000/microL). 2.Patients with hypocalcemia. 3.Patients scheduled to undergo kidney transplantation within 3 months. 4.Patients with an expected life expectancy of less than 3 months. 5.Patients with a known allergy to heparin or citrate.

Design outcomes

Primary

Measure	Time frame
catheter related infection at 6 months time to catheter related infection	—

Secondary

Measure	Time frame
catheter related thrombosis at 6 months time to catheter related thrombosis	—

Countries

Thailand

Contacts

Public Contactpachara Saengngammongkhol

Department of Medicine, Faculty of Medicine Ramathibodi Hospital

phat19941994@gmail.com022003606

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026